Please login to the form below

CAR-Ts

This page shows the latest CAR-Ts news and features for those working in and with pharma, biotech and healthcare.

Regeneron reveals first data for bispecific antibody in multiple myeloma

This includes CAR-Ts from Celgene/Bluebird Bio, Celgene/Juno, J&J/Legend Biotech, a drug antibody conjugate from GSK and a bispecific antibody from Amgen.

Latest news

Armed with new data, BMS plans filings for Celgene CAR-T liso-cel

respectively. The efficacy data looks similar on paper to the two approved CAR-Ts, though in a much larger group of patients, and BMS is also hoping to compensate for being ... Rates of serious adverse reactions in other CAR-T trials have tended to be
Gracell reports impressive data with one-day CAR-T for leukaemia

Those results suggest that FasT CAR19 – also known as GC007F) – could be a match clinically for already-marketed CD19 CAR-Ts from Novartis (Kymriah) and Gilead (Yescarta), but Gracell thinks its ... rival CD19-targeting CAR-Ts, plus seven days to
Regeneron's bispecific for lymphoma works in CAR-T failures

At the moment, Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) are the CAR-Ts that have been approved to treat DLBCL, with pivotal trials showing that they can ... In this trial, two patients who failed CAR-T
Encouraging early data for Amgen’s BiTE therapies

The potential is for the treatments to show superior efficacy to traditional antibodies, while having easier administration and fewer side-effects than CAR-Ts. ... If the BiTE technology is to mount a strong challenge to CAR-Ts, Amgen will want to
Bluebird’s myeloma CAR-T safety ‘could support outpatient use’

prior to the CAR-T and had a minimum of six months’ follow-up after bb2121 dosing. ... Along with CAR-Ts such as Novartis/Poseida’s P-BCMA-01 and Johnson &Johnson’s LCAR-B38M –incudes other therapeutic approaches in development include

More from news
Approximately 9 fully matching, plus 31 partially matching documents found.

Latest Intelligence

European biotech: a new generation of leaders emerges

year. The promise of the molecule is great, with analysts seeing it as a possible challenge to Novartis and Gilead’s CAR-T therapies. ... This means its clinical outcomes could match those seen in the CAR-Ts, but without the complexity and cost of
2019: CRISPR and therapeutic gene editing comes of age

TALEN is now being deployed most widely in chimeric antigen receptor T cell (CAR-T) therapies, which generally involve harvesting T cells from patients, modifying them to attack tumour cells by ... Companies like Cellectis and partner Allogene are
Deal Watch October 2018

FITC, which is not naturally present in the body, then becomes the target for CAR‐Ts expressing high affinity for FITC. ... Manufacture and supply of CAR‐T cell therapy, Kymriah, for B‐cell acute lymphoblastic leukaemia.
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

therapies, such as CAR-Ts Kymriah and Yescarta.
Cancer immunotherapy: What's on the horizon?

antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... The CAR-Ts have transformed the treatment

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

Understanding the evolving CAR-T market

In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are ... More than 500 CAR-Ts are in development, making competition fierce. Earlier this year
Blue Latitude Health

In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are ... Here, he explains what it was like to develop and deliver a groundbreaking CAR-T therapy

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Senior Medical Writer: Salary TBC

Senior / Principal Medical Writer – Medical Education - UK &...: Excellent Salary and Benefits on offer

Scientific Director - Medical Communications Agency - New York: Excellent Remuneration Package

Account Director, Medical Education: Salary TBC

Scientific Director - Medical Education - Cheshire & London ...: Excellent Remuneration Package

Experienced / Senior Medical Writer - MedComms - Cardiff - Wales: Excellent Salary and Benefits on offer

Account Director – Cheshire based Medical Communications Agency...: D.O.E

Graduate / Entry Level Opportunities – Medical Communications – ...: Highly Competitive Remuneration Package

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Senior Medical Writer – Leading Medical Communications Agency – ...: Highly Competitive Remuneration Package

Associate Medical Writer / Entry Level Medical Writer - Medical ...: DOE

Senior Medical Writer– Medical Education – Oxford - London: Excellent Remuneration Package

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Subscribe to our email news alerts

PMHub

Add my company

dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

The 2019 CPhI Pharma Index Report: Examining this year’s industry performance...
Five key trends in precision and personalised healthcare: Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications: Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...